Kerry Group Posts Lower Pretax Profit, Revenue on Muted Demand
By Nina Kienle
Kerry Group said pretax profit and revenue for the first half fell, as demand remained relatively muted given recent inflation across many geographies.
The Ireland-based food company said Wednesday that pretax profit was 364.8 million euros ($394.6 million) compared with EUR379.2 million for the first half of 2023.
Revenue fell to EUR3.88 billion from EUR4.12 billion in the year-prior period. The company said this compromised overall volume growth, but one division was ahead.
"Taste and nutrition delivered good volume growth ahead of our end markets, with strong profit growth and margin expansion across the business, contributing to our earnings per share growth of 9.1% in the period", Chief Executive Edmond Scanlon said.
The board declared an interim dividend of 38.1 European cents a share, up from 34.6 European cents in the year ago.
For 2024, the company updated its guidance, targeting constant currency adjusted earnings per share growth of 7% to 10%.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
July 31, 2024 03:02 ET (07:02 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks